Videos

Adam Dore, DO, discusses the recent developments in treating psoriatic arthritis and his predictions for the advancement of care in the upcoming year.

Carola Vinuesa, MD, PhD, recipient of the Lupus Research Alliance Lupus Insight Prize, discovered a mutation in a specific human gene that causes systemic lupus erythematosus.

Experts discuss known risk factors of fibromyalgia (FM).

Experts discuss the pathophysiology of fibromyalgia (FM) and how it relates to other chronic pain diseases.

Experts offer their clinical experience on why fibromyalgia (FM) is often misunderstood by patients and practitioners.

Wendy Wright, DNP, Kostas Botsoglou, MD, Daniel Clauw, MD, and Benjamin Natelson, MD, present an overview of symptoms and characteristics of fibromyalgia (FM).

Results found all clinical and patient-reported responses were statistically better with upadacitinib plus methotrexate compared with adalimumab plus methotrexate, although both treatments were effective.

The study stresses the need for better communication with patients and the impact of stress on both the rheumatic disease and mental health.

Results emphasized the challenges faced in accessing care and the impact on mental health for patients with rheumatic diseases.

Noortje van Herwaarden, MD, PhD, discusses the results of a 10-year follow-up from the DRESS study and how it informs use of disease activity-guided dose optimization in treatment of rheumatoid arthritis.

An analysis of DECT imaging from the MIRROR trial is providing clinicians with insight into the potential for urate crystal resolution and bone remodeling with pegloticase plus methotrexate in patients with uncontrolled gout.

An analysis of more than 20,000 people with type 2 diabetes suggests initiating therapy with an SGLT2 inhibitor, as a second-line treatment to metformin, was associated with a lower risk of developing gout relative to other second-line therapies.

Brian LaMoreaux, MD, discusses data from an analysis of the MIRROR trial examining the impact of pegloticase plus methotrexate on patient-reported outcomes and quality of life measures among patients with uncontrolled gout.

Janssen's efforts are accompanied by extensive data generation in patients of color and the creation of a diverse workforce.

Janssen aims to address health inequities and promote culturally competent care.

Dr David Hudesman, Dr Jordan Axelrad, and Dr Jose Scher discuss strategies for managing coexisting inflammatory bowel disease and psoriatic arthritis and highlight the importance of a multidisciplinary approach to providing comprehensive care.

Results of a recent study found that fibromyalgia may be more common among individuals with opioid use disorder, and that treating fibromyalgia may be beneficial for treating opioid use disorder.

Patients with fibromyalgia were more likely to report that pain caused them to continue using opioids, to increase the amount of opioids they used over time, and to delay getting addiction treatment.

Soumya Chakravarty, MD, PhD, discussed the results of the DISCOVER-1 and DISCOVER-2 studies that evaluated the long-term efficacy of guselkumab for the treatment of adult patients with active psoriatic arthritis.

Although the ultimate results of the study were unsurprising to Shai Efrati, MD, PhD, the magnitude of improvement was much higher than he and his team had anticipated.

Results of a recent study indicated that hyperbaric oxygen therapy significantly relieved symptoms of fibromyalgia.

Vibeke Strand, MD, MACR, FACP, shares the advantages and limitations of the AIMS and comparative cohort studies in the treatment of RA.

An expert rheumatologist discusses the Accelerate Information of Molecular Signatures (AIMS) study and the comparative cohort study of the MSRC test.

Vibeke Strand, MD, MACR, FACP, reviews the tools available to clinicians to improve treatment selection in RA, focusing on the molecular signature response classifier test.

Dr Vibeke Strand highlights the use of tumor necrosis factor inhibitors in the treatment of RA.

Vibeke Strand, MD, MACR, FACP, provides an overview of treatment options for rheumatoid arthritis.

Results of a recent study indicated that when a patient is able to temper their underlying disease, it can improve their experience of centrally sensitized pain despite not obtaining low disease activity.

Roy Fleischmann, MD, examined the necessity of performing repeated x-rays in patients with rheumatic disease as a part of disease management.

Pain, a key issue for patients with rheumatic diseases, is generally ranked as one of the top complaints of disease experience.

Philip Mease, MD, discusses other factors, besides drug inefficacy, that may impact pain in patients with rheumatic and autoimmune conditions.